Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD])

被引：0
|
作者：
Tabernero, J.
Aranda, E.
Gomez, A.
Massuti, B.
Sastre, J.
Abad, A.
Valladares, M.
Rivera, F.
Safont, M.
Diaz-Rubio, E.
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Hosp Reina Sofia, Cordoba, Spain
[3] Hosp Gen Alicante, Alicante, Spain
[4] Hosp Clin San Carlos, Madrid, Spain
[5] Univ Hosp Germans Trias & Pujol ICO, Barcelona, Spain
[6] Complejo Hosp Univ La Coruna, La Coruna, Spain
[7] Hosp Marques de Valdecilla, Cantabria, Spain
[8] Hosp Gen Valencia, Valencia, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3501
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish Cooperative Group for digestive tumor therapy (TTD).
    Grande, Enrique
    Guillen-Ponce, Carmen
    Vieitez de Prado, Jose Maria
    Reboredo, Margarita
    Duran, Gema
    Massuti Sureda, Bartolomeu
    Layos, Laura
    Salud, Antonia
    Faico, Esther
    Alonso, Vicente
    Garcia Alfonso, Pilar
    Jose Ortiz, Maria
    Sastre, Javier
    Rivera, Fernando
    Gallego, Javier
    Robles, Luis
    Gonzalez Astorga, Beatriz
    Dotor, Emma
    Carreto, Alfredo
    Aranda, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX)
    Cunningham, David
    Lang, Istvan
    Lorusso, Vito
    Ocvirk, Janja
    Shin, Dongbok
    Jonker, Derek J.
    Osborne, Stuart
    Andre, Niko Alexander
    Waterkamp, Daniel
    Saunders, Mark P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [43] Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) plus /- Trastuzumab as First-Line Treatment of Patients with Metastatic Breast Cancer (MBC)
    Schwartzberg, L. S.
    Hermann, R.
    Blakely, J.
    Richey, S. S.
    Tauer, K. W.
    Childs, B. H.
    CANCER RESEARCH, 2010, 70
  • [44] SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil plus bevacizumab (bev) versus capecitabine plus bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
    Andre, T.
    Saunders, M. P.
    Kanehisa, A.
    Gandossi, E.
    Fougeray, R.
    Causse-Amellal, N.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 250 - 250
  • [45] Regorafenib (REG) as a single agent for first-line treatment of frail and/ or unfit for polychemotherapy (PChT) patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).
    Carrato, Alfredo
    Benavides, Manuel
    Sureda, Bartolomeu Massuti
    Longo, Federico
    Alfonso, Pilar Garcia
    Falco, Esther
    Reboredo, Margarita
    Gomez-Espana, M. Auxiliadora
    Gallego, Javier
    Vieitez, Jose M.
    Salud, Antonia
    Alonso, Vicente
    Dotor, Emma
    Gil, Silvia
    Yuste, Ana
    Pachon, Vanesa
    Calvo, Aitana
    Grande, Enrique
    Aranda, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181
    Peeters, M.
    Price, T. J.
    Strickland, A. H.
    Ciuleanu, T. E.
    Scheithauer, W.
    O'Reilly, S.
    Keane, M. M.
    Spigel, D. R.
    Tian, Y.
    Krishnan, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial
    Tyagi, Preeta
    Grothey, Axel
    CLINICAL COLORECTAL CANCER, 2006, 6 (04) : 261 - 264
  • [48] Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and MOMA studies by GONO group.
    Rossini, Daniele
    Moretto, Roberto
    Cremolini, Chiara
    Zagonel, Vittorina
    Tonini, Giuseppe
    Ricci, Vincenzo
    Aprile, Giuseppe
    Lonardi, Sara
    Tomasello, Gianluca
    Dell'Aquila, Emanuela
    Allegrini, Giacomo
    Bergamo, Francesca
    Mancini, Marialaura
    Antoniotti, Carlotta
    Ronzoni, Monica
    Zaniboni, Alberto
    Marmorino, Federica
    Bustreo, Sara
    Mori, Elena
    Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] EFFICACY AND SAFETY OF TREATMENT WITH BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH BEV plus CT: AGE SUBGROUP ANALYSIS FROM A RANDOMISED PHASE III INTERGROUP STUDY (ML18147)
    Bouche, O.
    Steffens, C.
    Andre, T.
    Bennouna, J.
    Sastre, J.
    Osterlund, P.
    von Moos, R.
    Reyes-Rivera, I.
    Sersch, M. A.
    Arnold, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 190 - 191
  • [50] S-1/oxaliplatin (SOX) plus bevacizumab (Bev) as first line followed by S-1/irinotecan (IRIS) plus cetuximab (Cmab) as second line therapy in metastatic colorectal cancer (mCRC) (SOBIC trial)
    Nakamoto, Y.
    Mikami, R.
    Umeki, M.
    Tokunaga, Y.
    Okumoto, T.
    Kawamura, T.
    Fujiwara, H.
    Doi, S.
    Noda, M.
    Tomita, N.
    ANNALS OF ONCOLOGY, 2017, 28 : 44 - 44
12345